1-20 of 35
John M. Kirkwood
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B047: Monitoring treatment response and toxicity in BRAF V600-mutant metastatic melanoma with circulating cell-free DNA

Sidharth S Jain, A. Patrick IV McDeed, Megan E McNamara, Amber R Alley, Dori S Rosenstrauch, Harry Sun, Natalie Thompson, John M Kirkwood, Geoffrey T Gibney, Michael B Atkins, Anton Wellstein
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B047.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B047
Published: 13 November 2024
View article titled, Abstract B047: Monitoring treatment response and toxicity in BRAF V600-mutant metastatic melanoma with circulating cell-free DNA
Journal Articles

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein Tawbi, Johnathan A. Engh, Nduka M. Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H. Butterfield, Richard A. Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 521–531.
https://doi.org/10.1158/1078-0432.CCR-22-2581
Published: 01 February 2023
View article titled, Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Open the PDF for Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Andrew W. Hahn, Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M.A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y.N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina V. Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 154–164.
https://doi.org/10.1158/1078-0432.CCR-22-2661
Published: 04 January 2023
View article titled, Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Open the PDF for Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy

Lawrence P. Andrews, Anthony R. Cillo, Lilit Karapetyan, John M. Kirkwood, Creg J. Workman, Dario A.A. Vignali
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5030–5039.
https://doi.org/10.1158/1078-0432.CCR-21-2390
Published: 01 December 2022
View article titled, Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy
Open the PDF for Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy in another window
Journal Articles

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

Yana G. Najjar, Dustin McCurry, Huang Lin, Yan Lin, Yan Zang, Diwakar Davar, Arivarasan Karunamurthy, Joseph J. Drabick, Rogerio I. Neves, Lisa H. Butterfield, Marc S. Ernstoff, Igor Puzanov, Joseph J. Skitzki, Jennifer Bordeaux, IlaSri B. Summit, Jehovana O. Bender, Ju Young Kim, Beiru Chen, Ghanashyam Sarikonda, Anil Pahuja, Jennifer Tsau, Zeni Alfonso, Christian Laing, James F. Pingpank, Matthew P. Holtzman, Cindy Sander, Amy Rose, Hassane M. Zarour, John M. Kirkwood, Ahmad A. Tarhini
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4195–4204.
https://doi.org/10.1158/1078-0432.CCR-20-4301
Published: 01 August 2021
View article titled, Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Open the PDF for Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

The State of Melanoma: Emergent Challenges and Opportunities

Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne M. Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2678–2697.
https://doi.org/10.1158/1078-0432.CCR-20-4092
Published: 15 May 2021
View article titled, The State of Melanoma: Emergent Challenges and Opportunities
Open the PDF for The State of Melanoma: Emergent Challenges and Opportunities in another window
Journal Articles

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Joe-Marc Chauvin, Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio, Cindy Sanders, Jiajie Hou, Xian-Yang Li, Soldano Ferrone, Diwakar Davar, John M. Kirkwood, Robert J. Johnston, Alan J. Korman, Mark J. Smyth, Hassane M. Zarour
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5520–5533.
https://doi.org/10.1158/1078-0432.CCR-20-0575
Published: 15 October 2020
View article titled, IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Open the PDF for IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma in another window
Includes: Supplementary data
Journal Articles

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Benjamin Dizier, Andrea Callegaro, Muriel Debois, Brigitte Dreno, Peter Hersey, Helen J. Gogas, John M. Kirkwood, Johan F. Vansteenkiste, Lecia V. Sequist, Djordje Atanackovic, Jelle Goeman, Hans van Houwelingen, Susana Salceda, Fawn Wang, Patrick Therasse, Channa Debruyne, Bart Spiessens, Vincent G. Brichard, Jamila Louahed, Fernando Ulloa-Montoya
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1725–1735.
https://doi.org/10.1158/1078-0432.CCR-18-3717
Published: 01 April 2020
View article titled, A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer
Open the PDF for A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

Ahmad A. Tarhini, Sandra J. Lee, Xiaoxue Li, Uma N.M. Rao, Arun Nagarajan, Mark R. Albertini, Jerry W. Mitchell, Jr, Stuart J. Wong, Mark A. Taylor, Noel Laudi, Phu V. Truong, Robert M. Conry, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 524–532.
https://doi.org/10.1158/1078-0432.CCR-18-2258
Published: 15 January 2019
View article titled, E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Open the PDF for E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690

Mohammed Kashani-Sabet, Mehdi Nosrati, James R. Miller, III, Richard W. Sagebiel, Stanley P.L. Leong, Andrew Lesniak, Schuyler Tong, Sandra J. Lee, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6888–6892.
https://doi.org/10.1158/1078-0432.CCR-17-1317
Published: 14 November 2017
View article titled, Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690
Open the PDF for Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690 in another window
Journal Articles

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5034–5043.
https://doi.org/10.1158/1078-0432.CCR-16-3016
Published: 31 August 2017
View article titled, Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)
Open the PDF for Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) in another window
Includes: Supplementary data
Journal Articles

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 374–382.
https://doi.org/10.1158/1078-0432.CCR-15-1162
Published: 14 January 2016
View article titled, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Open the PDF for Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux

Diwakar Davar, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5412–5414.
https://doi.org/10.1158/1078-0432.CCR-14-3132
Published: 14 December 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux in another window
Journal Articles

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

Melissa A. Wilson, Fengmin Zhao, Richard Letrero, Kurt D'Andrea, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Sandra J. Lee, Lynn M. Schuchter, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3328–3337.
https://doi.org/10.1158/1078-0432.CCR-14-0093
Published: 12 June 2014
View article titled, Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Open the PDF for Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib in another window
Includes: Supplementary data
Journal Articles

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarhini, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6597–6604.
https://doi.org/10.1158/1078-0432.CCR-13-1414
Published: 01 December 2013
View article titled, ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
Open the PDF for ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

Craig L. Slingluff, Jr, Sandra Lee, Fengmin Zhao, Kimberly A. Chianese-Bullock, Walter C. Olson, Lisa H. Butterfield, Theresa L. Whiteside, Philip D. Leming, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4228–4238.
https://doi.org/10.1158/1078-0432.CCR-13-0002
Published: 31 July 2013
View article titled, A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
Open the PDF for A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602) in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

Kim A. Margolin, James Moon, Lawrence E. Flaherty, Christopher D. Lao, Wallace L. Akerley, III, Megan Othus, Jeffrey A. Sosman, John M. Kirkwood, Vernon K. Sondak
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1129–1137.
https://doi.org/10.1158/1078-0432.CCR-11-2488
Published: 14 February 2012
View article titled, Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
Open the PDF for Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) in another window
Journal Articles

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 555–567.
https://doi.org/10.1158/1078-0432.CCR-11-1491
Published: 16 January 2012
View article titled, Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
Open the PDF for Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

New Challenges in Endpoints for Drug Development in Advanced Melanoma

Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 336–341.
https://doi.org/10.1158/1078-0432.CCR-11-2323
Published: 16 January 2012
View article titled, New Challenges in Endpoints for Drug Development in Advanced Melanoma
Open the PDF for New Challenges in Endpoints for Drug Development in Advanced Melanoma in another window
Journal Articles

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M. Shi, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7451–7461.
https://doi.org/10.1158/1078-0432.CCR-11-1747
Published: 30 November 2011
View article titled, Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
Open the PDF for Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma in another window
Includes: Supplementary data